![](/wp-content/uploads/2024/07/Screenshot-2024-07-26-at-9.12.13%E2%80%AFAM.png)
$599
Dexcom Q2 ’24 Earnings
Dexcom hosted its Q2 ’24 earnings call (press release; slides) and provided updates across its business, including the impending launch of its first OTC CGM (Stelo). Dexcom lowered its full-year guidance which has led to a ~38% drop in the company’s stock price. Below, FENIX provides highlights and insights from the call.